Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi -110062, Delhi, India.
Toxicol Mech Methods. 2012 Jan;22(1):67-73. doi: 10.3109/15376516.2011.603391. Epub 2011 Aug 23.
There has been a steady increase in the epidemiology of obesity over the last 30 years with developed countries leading the way. Oxidative stress was believed to be the principle contributor to the development of cardiovascular disorders that linked with obesity.
To evaluate the enhancement of antioxidant defense mechanism by Pitavastatin (PTV) and Rosuvastatin (RSV) on obesity-induced oxidative stress in Wistar rats.
Fifty Wistar albino rats were divided into five groups. High fat diet (HFD, 20 g/day/rat) pellets were given for 28 days to produce obesity-induced oxidative stress in Wistar rats. Oral administration of HFD along with PTV, RSV and Orlistat [(HFD for 28 days + from 8th day PTV (1 mg/kg), RSV (5 mg/kg) and Orlistat (10 mg/kg) to 28th day] were given respectively.
Both PTV and RSV produced significant (p < 0.01) reduction in serum apolipoprotein-B (Apo-B), total cholesterol (TC), triglycerides (TGs), cardiac-lipid peroxides (TBARS) levels and elevation in serum high density lipoprotein (HDL-C), cardiac antioxidant enzymes [glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST), superoxide dismutase (SOD) and catase (CAT)] levels.
Results were comparable with Orlistat, a standard antiobesity drug and present initial evidence that Pitavastatin and Rosuvastatin are useful for the treatment of obesity by enhancing the antioxidant defense mechanism. However, the effects of PTV were more prominent than RSV. The present findings of Pitavastatin and Rosuvastatin raise the possibility of a new application as an antiobesity therapeutic modality.
在过去的 30 年中,肥胖症的流行病学一直在稳步增加,发达国家处于领先地位。氧化应激被认为是导致与肥胖相关的心血管疾病发展的主要因素。
评估匹伐他汀(PTV)和罗苏伐他汀(RSV)对肥胖诱导的 Wistar 大鼠氧化应激的抗氧化防御机制的增强作用。
将 50 只 Wistar 白化大鼠分为五组。给予高脂肪饮食(HFD,20 g/天/大鼠)颗粒 28 天,以在 Wistar 大鼠中产生肥胖诱导的氧化应激。分别给予 HFD 口服给药以及 PTV、RSV 和奥利司他[(28 天 HFD+第 8 天开始 PTV(1mg/kg)、RSV(5mg/kg)和奥利司他(10mg/kg)至第 28 天]。
PTV 和 RSV 均显著降低血清载脂蛋白-B(Apo-B)、总胆固醇(TC)、甘油三酯(TGs)、心脏脂质过氧化物(TBARS)水平(p<0.01),并升高血清高密度脂蛋白(HDL-C)、心脏抗氧化酶[谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GPx)、谷胱甘肽还原酶(GR)、谷胱甘肽-S-转移酶(GST)、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)]水平。
结果与奥利司他(一种标准的减肥药)相当,这初步证明匹伐他汀和罗苏伐他汀通过增强抗氧化防御机制对肥胖症的治疗有用。然而,PTV 的效果比 RSV 更为显著。匹伐他汀和罗苏伐他汀的现有发现提出了将其作为一种新的减肥治疗方法的可能性。